Prostanoid receptor antagonists: development strategies and therapeutic applications

Area of Science:

• Pharmacology and Drug Discovery
• Molecular Biology
• Inflammation Research

Background:

• Prostanoid receptors (DP, EP, FP, IP, TP) were classified based on agonist/antagonist pharmacology.
• Development of selective antagonists varied across receptor types, with some still lacking potent options.

Purpose of the Study:

• To review the development strategies and clinical utility of various prostanoid receptor antagonist classes.
• To highlight the role of selective antagonists in elucidating prostaglandin functions in inflammatory conditions.
• To assess the therapeutic potential and limitations of current and emerging antagonist therapies.

Main Methods:

• Analysis of historical data on cyclo-oxygenase (COX) products and prostanoid receptor classification.
• Review of drug discovery approaches, including high-throughput screening and recombinant receptor assays.
• Evaluation of pharmacological data for natural and synthetic agonists and antagonists.
• Assessment of clinical trial outcomes and safety profiles for approved and investigational antagonists.

Main Results:

• Selective antagonists have been instrumental in defining the roles of PGD(2) and PGE(2) in inflammation.
• Development of non-prostanoid antagonists (e.g., acyl-sulphonamides) has accelerated via high-throughput screening.
• TP antagonists show limited success in cardiovascular applications, while IP antagonist utility is debated due to COX-2 inhibitor safety concerns.

Conclusions:

• Targeted therapies for inflammatory conditions are possible through selective prostanoid receptor antagonism.
• Achieving intermediate selectivity profiles may offer a balance between broad COX inhibition and high receptor specificity.
• Further research into antagonist development and clinical application is warranted for optimized therapeutic interventions.